It has also been identified as a mediator of resistance to venetoclax/azacitidine, and the inhibition of RPS6KA1 may serve as a strategy to prevent or overcome resistance in the treatment of acute myeloid leukemia (Weidenauer et al., 2023; Yu et al., 2021). The gene discussed is RPS6KA1; the disease is acute myeloid leukemia.